Drug intelligence / Profile preview

ODC-B

Development stage: Preclinical
Lead developer: Trutino Biosciences
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes

Overview

ODC-B is a preclinical, next-generation cytokine therapy developed by Trutino Biosciences as part of its "On Demand Cytokine" platform. This platform aims to deliver cytokine-based therapeutic effects. Boehringer Ingelheim has an option to acquire Trutino Biosciences, building on a 2020 research partnership, with the rationale to integrate Trutino's cytokine platform into Boehringer's immuno-oncology pipeline.

Targets

Cr (Chromium)

Beyond the preview

Go deeper on ODC-B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ODC-B.

Explore the full profile